ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
IMRICOR MEDICAL SYSTEMS-CDI
1.845
-0.005
-0.27%
成交量:
75.80萬
成交額:
140.03萬
市值:
6.62億
市盈率:
-10.74
高:
1.930
開:
1.900
低:
1.825
收:
1.850
52周最高:
2.250
52周最低:
1.275
股本:
3.59億
流通股本:
2.75億
量比:
0.73
換手率:
0.28%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.172
每股收益(LYR):
-0.115
淨資產收益率:
-143.12%
總資產收益率:
-26.53%
市淨率:
16.23
市盈率(LYR):
-16.05
資料載入中...
總覽
公司
新聞資訊
公告
Imricor Medical Systems預期獲FDA批准,新增資本設備將拓寬美國市場產品線
美股速递
·
08/10
Imricor Medical Systems 提交Navtrac與Navtrac-mr可控導引器尋求美國FDA 510(k)許可
美股速递
·
07/20
Imricor Medical Systems股價上漲,因兩款設備獲得美國FDA批准
路透中文
·
07/02
Imricor Medical Systems獲FDA 510(k)許可 擴大Vision-Mr診斷導管兒科適應症標籤
美股速递
·
07/02
Imricor Medical Systems提交產品組合,含Vision-Mr消融導管2型、RF-5000發生器及RF-5000管路套件
美股速递
·
06/11
Imricor Medical系統公司因擬議融資公告申請暫停交易
美股速递
·
04/30
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IMR.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMR.AU\",,,,,undefined,":{"symbol":"IMR.AU","market":"AU","secType":"STK","nameCN":"IMRICOR MEDICAL SYSTEMS-CDI","latestPrice":1.845,"timestamp":1789452720000,"preClose":1.85,"halted":0,"volume":757999,"delay":0,"changeRate":-0.002702702702702765,"nameEN":"IMRICOR MEDICAL SYSTEMS-CDI","floatShares":275046474,"shares":358542497,"eps":-0.1717583582449508,"marketStatus":"未開盤","change":-0.005,"latestTime":"09-15 16:12:00 AEST","open":1.9,"high":1.93,"low":1.825,"amount":1400333,"amplitude":0.056757,"askPrice":1.94,"askSize":4142,"bidPrice":1.8,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.1717583582449508,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.85,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":0.733633,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMR.AU","preClose":1.85,"auctionPrice":1.845,"auctionVolume":2690,"auction":3,"marketStatus":"盘后竞价","timestamp":1789452600502}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMR.AU\",,,,,undefined,":{"symbol":"IMR.AU","floatShares":275046474,"roa":"-26.53%","roe":"-143.12%","lyrEps":-0.114981,"volumeRatio":0.733633,"shares":358542497,"dividePrice":0,"high":1.93,"amplitude":0.056757,"preClose":1.85,"low":1.825,"week52Low":1.275,"pbRate":"16.23","psRate":"3928.99","week52High":2.25,"institutionHeld":0,"latestPrice":1.845,"committee":0.093853,"eps":-0.1717583582449508,"divideRate":0,"volume":757999,"delay":0,"ttmEps":-0.1717583582449508,"open":1.9,"prevYearClose":1.53,"prevWeekClose":1.82,"prevMonthClose":1.945,"prevQuarterClose":1.845,"fiveDayClose":1.895,"twentyDayClose":2.07,"sixtyDayClose":1.83,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMR.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-10","symbol":"IMR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786320000000,"name":null,"time":"","dateTimestamp":1786284000000,"actualEps":null},{"date":"2026-02-24","symbol":"IMR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771887600000,"name":null,"time":"","dateTimestamp":1771851600000,"actualEps":null},{"date":"2025-08-26","symbol":"IMR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756166400000,"name":null,"time":"","dateTimestamp":1756130400000,"actualEps":null},{"date":"2025-02-26","symbol":"IMR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-28","symbol":"IMR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724803200000,"name":null,"time":"","dateTimestamp":1724767200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMR.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170228291","title":"Imricor Medical Systems預期獲FDA批准,新增資本設備將拓寬美國市場產品線","url":"https://stock-news.laohu8.com/highlight/detail?id=1170228291","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170228291?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 06:40","pubTimestamp":1786315209,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems(IMRICOR MEDICAL SYSTEMS-CDI)预计将获得美国食品药品监督管理局(FDA)对更多资本设备的审批许可。此举有望显著扩展该公司向美国客户提供的产品组合,进一步丰富其市场供给。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","IMR.AU","BK7508","BK7503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133376223","title":"Imricor Medical Systems 提交Navtrac與Navtrac-mr可控導引器尋求美國FDA 510(k)許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1133376223","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133376223?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 07:26","pubTimestamp":1784503570,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems 已正式向美国食品药品监督管理局提交了其Navtrac与Navtrac-mr可控导引器,以寻求510(k)市场准入许可。这一步骤标志着该公司在推进其创新医疗设备商业化进程中的关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7007","BK7503","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648520080","title":"Imricor Medical Systems股價上漲,因兩款設備獲得美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648520080","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648520080?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 09:14","pubTimestamp":1782954879,"startTime":"0","endTime":"0","summary":"BUZZ-Imricor Medical Systems股价上涨,因两款设备获得美国FDA批准7月2日-** 在澳大利亚证券交易所(ASX)上市的Imricor Medical Systems公司(IMR.AX)股价一度上涨16.3%,至2.1澳元,创下自4月下旬以来的最高水平** 这家总部位于美国的医疗设备制造商 (link) 的NorthStar定位系统和Vision-MR诊断导管获得美国食品药品监督管理局(FDA)批准,将适应症范围扩展至儿科患者** 此次批准将使该公司能够将这两款产品推广至所有年龄段的患者,包括儿童和青年** 该股今年以来累计涨幅已超过30%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nL4T43402U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","IMR.AU","BK7508","BK7503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124120626","title":"Imricor Medical Systems獲FDA 510(k)許可 擴大Vision-Mr診斷導管兒科適應症標籤","url":"https://stock-news.laohu8.com/highlight/detail?id=1124120626","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124120626?lang=zh_tw&edition=fundamental","pubTime":"2026-07-02 06:37","pubTimestamp":1782945436,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems宣布,其Vision-Mr诊断导管已获得美国食品药品监督管理局(FDA)的510(k)许可,用于扩大儿科适应症的标签范围。这一监管批准标志着该产品在儿科心脏介入磁共振成像领域应用的重要拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","BK7508","BK7503","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136030685","title":"Imricor Medical Systems提交產品組合,含Vision-Mr消融導管2型、RF-5000發生器及RF-5000管路套件","url":"https://stock-news.laohu8.com/highlight/detail?id=1136030685","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136030685?lang=zh_tw&edition=fundamental","pubTime":"2026-06-11 06:57","pubTimestamp":1781132237,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems-CDI已提交产品组合,其中涵盖了第二代Vision-Mr消融导管、RF-5000发生器以及RF-5000管路套件。这一提交标志着公司在心脏消融治疗技术领域的产品线拓展。Vision-Mr消融导管2型专为磁共振引导下的精准消融手术设计,而RF-5000发生器与其配套的管路套件则共同构成了一个高效、集成的射频消融系统。该组合有望提升手术的精确度与安全性,为临床医生提供更先进的工具选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7007","BK7503","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113867007","title":"Imricor Medical系統公司因擬議融資公告申請暫停交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1113867007","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113867007?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 08:02","pubTimestamp":1777507335,"startTime":"0","endTime":"0","summary":"Imricor Medical系统公司今日向澳大利亚证券交易所提交申请,要求暂停其证券交易。此次交易暂停旨在等待公司发布关于拟议资本筹集计划的重要公告。\n市场人士指出,交易暂停通常意味着公司即将公布可能影响股价的重大信息。Imricor Medical作为心脏介入治疗设备领域的创新企业,此次资本运作备受投资者关注。\n公司表示将在适当时候披露融资方案的具体细节,包括融资规模、定价机制及资金用途等重要信息。此举被视为公司为后续业务拓展进行战略布局的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7508","BK7007","IMR.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}